FIBROTARGET

FIBROTARGET is paving the way to change the status quo in inflammatory bowel disease (IBD) 🌄 . A large part of this project involves investigation into development of novel therapeutics for inflammatory fibrosis and fibrostenosis. We caught up with one of FIBROTARGET's researchers🔬, Victoria Gudiño, PhD, based at Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) – Hospital Clínic de Barcelona. Read the full interview as we discuss Victoria's roles and responsibilities within the FIBROTARGET project, and what it means for advancing IBD fibrosis treatment. 🗞️Read the full interview here➡️ https://loom.ly/tQKNvNI #IBD #Research #Innovation #FIBROTARGET

🌍 Health Resources for Everyone 🌍 Understanding your health should be simple and accessible. That’s why the FIBROTARGET factsheet, developed with European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA), is now available in English, Dutch, Spanish, German, French, and Italian. These resources provide critical insights on IBD-related fibrosis to more people than ever before. 🌟🔬Get informed and feel empowered to be part of fibrosis and fibrostenosis research. Download the factsheet in your language here➡️https://loom.ly/yW8mEBc #IBD #Translations #FIBROTARGET #PatientEmpowerment With thanks to contributions from: Crohn en Colitis ulcerosa vereniging vzw, Asbl Crohn RCUH, AMICI Italia - Associazione nazionale per le Malattie Infiammatorie Croniche dell'Intestino, ACCU ESPAÑA, DCCV e.V. Project Partners: European Federation of Crohn's and Ulcerative Colitis Associations (Isabella Haaf), Teamit (Eva Molero Romen, Gisela Pairó, Sarai Rodríguez Navarro, Fabio Riefolo, PharmD - PhD, Sofia Sintoris), UZ Leuven KU Leuven (Severine Vermeire, Gianluca Matteoli), Motilent (Alex Menys, Beth Fisher), Hospital Clínic de Barcelona, Amyndas Pharmaceuticals, Universitätsklinikum Erlangen, Crohn's & Colitis Foundation, Crohn's & Colitis UK, Crohn's and Colitis Young Adults Network

European Federation of Crohn's and Ulcerative Colitis Associations and FIBROTARGET: close collaboration for patient-centred research in fibrosis and fibrostenosis👥🔬 In FIBROTARGET, EFCCA plays a crucial role in bridging the gap between scientific innovation and the needs of the IBD community by providing 💭patient perspectives and insights💭 that drive the project’s aim to develop new approaches to treat or prevent intestinal fibrosis and fibrostenosis—currently unmet needs in IBD care. We caught up with Isabella Haaf, Head of Communications at European Federation of Crohn's and Ulcerative Colitis Associations, to discuss our collaboration, including the creation of the multilingual FIBROTARGET factsheet. Read the full interview here➡️[https://loom.ly/ruVk9FU]

🌍 FIBROTARGET Factsheet now available in multiple languages! 🌍 Understanding your health should never be limited by language. That’s why we’re excited to share that our FIBROTARGET factsheet is now available in English, Dutch, Spanish, German, French, and Italian—making our insights on IBD-related fibrosis accessible to even more of the community. Developed in collaboration with the European Federation of Crohn's and Ulcerative Colitis Associations, this resource is designed to: ✅ Provide clear, concise information on our project’s goals and progress. ✅ Keep you informed about the latest research on intestinal fibrosis and fibrostenosis. ✅ Empower the IBD community with resources in your language. Let’s break barriers together and ensure everyone feels included and informed. Download the factsheet today and join us in advancing the future of IBD care! 👉 https://loom.ly/yW8mEBc With thanks to contributions from: Crohn en Colitis ulcerosa vereniging vzw, Asbl Crohn RCUH, AMICI Italia - Associazione nazionale per le Malattie Infiammatorie Croniche dell'Intestino, ACCU España, DCCV e.V. Project Partners: European Federation of Crohn's and Ulcerative Colitis Associations (Isabella Haaf), Teamit (Eva Molero Romen, Gisela Pairó, Sarai Rodríguez Navarro, Fabio Riefolo, PharmD - PhD, Sofia Sintoris), UZ Leuven KU Leuven (Severine Vermeire, Gianluca Matteoli), Motilent (Alex Menys, Beth Fisher), Hospital Clínic de Barcelona, Amyndas Pharmaceuticals, Universitätsklinikum Erlangen, Crohn's & Colitis Foundation Crohn's & Colitis UK Crohn's and Colitis Young Adults Network #IBD #FIBROTARGET #PatientEmpowerment #EFCCA

Have you seen the latest Projects Digest from European Federation of Crohn's and Ulcerative Colitis Associations? In this latest issue, patient federation and Consortium partner, EFFCA, discusses latest updates in FIBROTARGET including our 5th Virtual GAM👥, an upcoming webinar on fibrosis diagnosis and treatment💻, and a new collaborative project flyer🗞️. FIBROTARGET aims to advance the prevention🚫, diagnosis👩⚕️ and treatment💊 of intestinal fibrosis and fibrostenosis in IBD. How? Our goal is to identify biomarkers for early fibrosis detection, test new diagnostic techniques and develop predictive models, laying the groundwork for personalised anti-fibrotic treatments to improve patient quality of life. Read the European Federation of Crohn's and Ulcerative Colitis Associations project digest here ➡️ https://loom.ly/67pEd2k Interested in learning more about FIBROTARGET and how we are putting patients at the centre of research? Check out our website ➡️ https://loom.ly/IGYRLgM European Federation of Crohn's and Ulcerative Colitis Associations Teamit KU Leuven Crohn's & Colitis Foundation Crohn's & Colitis UK Crohn's and Colitis Young Adults Network Motilent Fundació Clínic per a la Recerca Biomèdica, Hospital Clínic de Barcelona, Universitätsklinikum Erlangen, Amyndas Pharmaceuticals

With the right people, right funding, and right opportunity, we at FIBROTARGET are creating the momentum needed to turn possibilities into breakthroughs in research 🔬 . Read below from project co-coordinator Severine Vermeire (KU Leuven), whose leadership is helping to drive the consortium closer to advancing #IBD fibrosis diagnosis and therapies. More about Dr. Severine Vermeire and her contributions to the field here ⤵️ https://lnkd.in/dE5N8F5W

👏 Proud to share that FIBROTARGET partner Motilent is making significant strides in advancing #intestinalfibrosis and Crohn’s Disease research. Their cutting-edge MRI post-processing software, #GIQuant and #GISeg, is transforming how clinicians and researchers approach the gut 🔬 , providing quantitative endpoints that are critical for understanding treatment response in small bowel Crohn’s Disease. Discover more about their latest studies in the field and how these tools 🖥 could prove indispensable for #FIBROTARGET’s mission to enhance the prevention, diagnosis, and care of intestinal fibrosis and fibrostenosis. 🔗 https://lnkd.in/dEnsr5Nq #MedicalImaging #CrohnsDisease #IntestinalFibrosis #InflammatoryBowelDisease #HealthcareInnovation Alex Menys Beth Fisher European Federation of Crohn's and Ulcerative Colitis Associations Isabella Haaf Eva Molero Romen Sarai Rodríguez Navarro Judith Palou Biosca Alessandro Armuzzi Jordi Rimola European Society of Gastrointestinal and Abdominal Radiology - ESGAR Severine Vermeire Gianluca Matteoli Bram Verstockt UEG - United European Gastroenterology

Last week, FIBROTARGET published a scientific article 🔬on our website (https://lnkd.in/dBeP_GiH), focusing on the intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates #fibrostenosis in Crohn’s disease. To make sure that patients and everyday citizens, especially, can know and share what's being discussed in #FIBROTARGET, we're passing along our latest Glossary of Terms 📖 . Take a look below and repost as we highlight keywords from the scientific publication and what it means within the context of #IBD. ⤵ ⤵⤵ European Federation of Crohn's and Ulcerative Colitis Associations Teamit Eva Molero Romen Gisela Pairó Severine Vermeire UZ Leuven KU Leuven Crohn's & Colitis Foundation Crohn's & Colitis UK Crohn's and Colitis Young Adults Network Alessandro Armuzzi Motilent Alex Menys Gianluca Matteoli Bo-Jun Ke Beth Fisher The Journal of Clinical Investigation Sneha Santhosh Lies van Baarle Sarai Rodríguez Navarro Fabio Riefolo, PhD Luisa Avedano Isabella Haaf

📝 We're excited to announce a new publication from FIBROTARGET on the pathogenesis of fibrotic stricture in Crohn’s disease in The Journal of Clinical Investigation  ⤵ 💭 What role does TWIST1 (a protein) have in pathogenic (disease-causing) #fibroblasts? Although much research 🔬 has taken place throughout the years, individuals living with Crohn’s disease continue to face a risk of developing this health complication (at least 30-40% may experience a stricture over the course of the disease). 🔎 Discover more about the paper and its potential implications: https://lnkd.in/dBeP_GiH #Crohnsdisease #pavingtheway

📢 Exciting Update for the IBD Community! 📢 We are pleased to share our FIBROTARGET flyer, highlighting our mission (and more) to improve the prevention, diagnosis, and treatment of intestinal fibrosis and fibrostenosis. This flyer was created 🤝 in collaboration with patient organisation European Federation of Crohn's and Ulcerative Colitis Associations to ensure that those living with #IBD can learn more about what's being done to change the #statusquo with this disease. The flyer will soon be available in multiple European 🇪🇺 languages to reach and inform more people across the continent. Feel free to take a look at the flyer, download, and repost!* 👇 *📩 For more information or to get involved, contact us at info@fibrotarget.eu Eva Molero Romen Gisela Pairó Sarai Rodríguez Navarro Judith Palou Biosca Isabella Haaf Luisa Avedano Salvo Leone Severine Vermeire Gianluca Matteoli KU Leuven Gaia Zanella Bo-Jun Ke Bram Verstockt Despina Yancopoulou Beth Fisher Alex Menys Motilent Azucena Salas Jordi Rimola UEG - United European Gastroenterology Fabio Riefolo, PhD Victoria Gudiño, PhD